Details for Patent: 11,020,382
✉ Email this page to a colleague
Which drugs does patent 11,020,382 protect, and when does it expire?
Patent 11,020,382 protects OXBRYTA and is included in two NDAs.
This patent has ten patent family members in eight countries.
Summary for Patent: 11,020,382
| Title: | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde |
| Abstract: | Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzal- dehyde (Compound 1), or a polymorph thereof, in certain dosing regimens. |
| Inventor(s): | Ramos; Eleanor L. (South San Francisco, CA), Lehrer-Graiwer; Joshua Eli (South San Francisco, CA), Hutchaleelaha; Athiwat (South San Francisco, CA) |
| Assignee: | Global Blood Therapeutics, Inc. (South San Francisco, CA) |
| Application Number: | 15/368,142 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 11,020,382
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,020,382
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112018011272 | ⤷ Sign Up | |||
| European Patent Office | 3383392 | ⤷ Sign Up | |||
| Israel | 259798 | ⤷ Sign Up | |||
| Morocco | 43373 | ⤷ Sign Up | |||
| Mexico | 2018006832 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
